相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Ian M. Silverman et al.
CANCER DISCOVERY (2021)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma
Fangda Li et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2020)
Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
Melanie A. Krook et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
Sunil K. Joshi et al.
LEUKEMIA (2020)
The mutational constraint spectrum quantified from variation in 141,456 humans
Konrad J. Karczewski et al.
NATURE (2020)
Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Vivek Subbiah et al.
LANCET ONCOLOGY (2020)
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
Martin H. Voss et al.
CLINICAL CANCER RESEARCH (2019)
Targeted Cancer Next-Generation Sequencing as a Primary Screening Tool for Microsatellite Instability and Lynch Syndrome in Upper Gastrointestinal Tract Cancers
Alexander G. Christakis et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2019)
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
Rastislav Bahleda et al.
CLINICAL CANCER RESEARCH (2019)
ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC plus mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
Angela Lamarca et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2019)
Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports
Kenneth L. Kehl et al.
JAMA ONCOLOGY (2019)
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro et al.
BRITISH JOURNAL OF CANCER (2019)
Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
Alison M. Schram et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Structure and function of RET in multiple endocrine neoplasia type 2
Ivan Plaza-Menacho
ENDOCRINE-RELATED CANCER (2018)
Cholangiocarcinoma - evolving concepts and therapeutic strategies
Sumera Rizvi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
O-001Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors
F Meric-Bernstam et al.
ANNALS OF ONCOLOGY (2018)
Systematic Functional Annotation of Somatic Mutations in Cancer
Patrick Kwok-Shing Ng et al.
CANCER CELL (2018)
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
Maeve A. Lowery et al.
CLINICAL CANCER RESEARCH (2018)
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma
David J. Papke et al.
MODERN PATHOLOGY (2018)
LBA28Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
M Javle et al.
ANNALS OF ONCOLOGY (2018)
Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
Carman K. M. Ip et al.
NATURE COMMUNICATIONS (2018)
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2017)
Fibroblast Growth Factor Receptor 2 (FGFR2) Mutation Related Syndromic Craniosynostosis
Said C. Azoury et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2017)
New Horizons for Precision Medicine in Biliary Tract Cancers
Juan W. Valle et al.
CANCER DISCOVERY (2017)
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Apinya Jusakul et al.
CANCER DISCOVERY (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm
D. A. Casolari et al.
SCIENTIFIC REPORTS (2017)
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshad Farshidfar et al.
CELL REPORTS (2017)
Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data
Italo Faria do Valle et al.
BMC BIOINFORMATICS (2016)
Ectrodactyly and Lethal Pulmonary Acinar Dysplasia Associated with Homozygous FGFR2 Mutations Identified by Exome Sequencing
Christopher P. Barnett et al.
HUMAN MUTATION (2016)
Pathogenic Cysteine Removal Mutations in FGFR Extracellular Domains Stabilize Receptor Dimers and Perturb the TM Dimer Structure
Sarvenaz Sarabipour et al.
JOURNAL OF MOLECULAR BIOLOGY (2016)
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
Konstantinos J. Mavrakis et al.
SCIENCE (2016)
f Institutional implementation of clinical tumor profiling on an unselected cancer population
Lynette M. Sholl et al.
JCI INSIGHT (2016)
Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2
Junko Tanizaki et al.
CANCER RESEARCH (2015)
Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations
Leandro H. Gallo et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2015)
Genome-Wide Analysis of Gene-Gene and Gene-Environment Interactions Using Closed-Form Wald Tests
Zhaoxia Yu et al.
GENETIC EPIDEMIOLOGY (2015)
Genomic spectra of biliary tract cancer
Hiromi Nakamura et al.
NATURE GENETICS (2015)
BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers
Ryan P. Abo et al.
NUCLEIC ACIDS RESEARCH (2015)
Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
Yasuhito Arai et al.
HEPATOLOGY (2014)
A Novel FGFR2 Mutation in Tyrosine Kinase ll Domain, L617F, in Crouzon Syndrome
Ye-Jin Suh et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2014)
ClinVar: public archive of relationships among sequence variation and human phenotype
Melissa J. Landrum et al.
NUCLEIC ACIDS RESEARCH (2014)
Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma
Rachel G. Liao et al.
CANCER RESEARCH (2013)
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Yuchen Jiao et al.
NATURE GENETICS (2013)
Activating Somatic FGFR2 Mutations in Breast Cancer
Nadine Reintjes et al.
PLOS ONE (2013)
p38 Inhibition ameliorates skin and skull abnormalities in Fgfr2 Beare-Stevenson mice
Yingli Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Novel FGFR2 Deletion in a Patient With Beare-Stevenson-Like Syndrome
Anne Slavotinek et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2009)
Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma
Michael G. Gartside et al.
MOLECULAR CANCER RESEARCH (2009)
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Amit Dutt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes
P. M. Pollock et al.
ONCOGENE (2007)
A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis
VP Eswarakumar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis
S Kan et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2002)
Pfeiffer syndrome type 2 associated with a single amino acid deletion in the FGFR2 gene
M Priolo et al.
CLINICAL GENETICS (2000)
Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts
A Mansukhani et al.
JOURNAL OF CELL BIOLOGY (2000)
分享论文
